Tanner Health and Healthliant Ventures have launched a partnership with Australian medical technology company Artrya Limited. Artrya is focused on commercializing its patented AI platform that detects key coronary artery disease imaging markers.
“Tanner Health is the second major hospital group we have partnered with in the U.S. over the past few months as part of our commercialization strategy to enter the U.S. market,” said Artrya Chief Executive Officer Mathew Regan. “Our approach is to embed our technology into large hospital systems while simultaneously progressing with FDA regulatory clearance. This means that post FDA clearance we can quickly rollout and expand Salix Coronary Anatomy (SCA) into these hospital groups.”
Under the agreement, Tanner Health will work with Artrya in an Innovation Participation Agreement to non-clinically validate and test Salix Coronary Anatomy (SCA) into Tanner Health's workflow while the product is going through the FDA 510(k) clearance process.
“Artrya's Salix Coronary Anatomy solution is a game-changer in the assessment of coronary artery disease,” said Shazib Khawaja, MD, FACC, FSCAI, a board-certified cardiovascular disease and interventional cardiology specialist and chief of interventional cardiology at Tanner Health. “Despite the billions we spend each year on heart disease, it is still unfortunately the number one cause of death worldwide — killing more people than all cancers combined.
“Many individuals who experience a heart attack may not have any long-term symptoms. Salix allows clinicians to accurately detect the primary cause of heart disease, vulnerable plaque," said Dr. Khawaja.
The organizations will also develop and expand the specific use cases for Artrya’s software products across five hospitals, nine outpatient centers, dedicated heart and vascular centers and accredited chest pain centers that form part of Tanner Health.
"I’m excited for our clinicians to use Salix as I believe the technology will help us more accurately determine which patients should be admitted for emergency care,” said Tanner Health’s Executive Vice President, Chief Medical Officer and Chief Quality Officer, Benjamin Camp, MD. “Up to 90% of chest pain patients are admitted to the emergency department unnecessarily and should stay in primary care, and one in 13 patients discharged from emergency department for non-specific chest pain return to the hospital within seven days. ”
Post-FDA pre-market clearances, Tanner Health will work with Artrya to rollout and expand its point-of-care SCA solution to clinicians and patients across their health network in west Georgia and east Alabama.
"The confidence Dr. Khawaja and Dr. Camp have shown in Salix demonstrates the potential of our AI-driven technology to significantly improve the diagnosis and care for the global number one killer, heart disease,” said Regan.
About Artrya
Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.
Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.
For more information, visit Artrya.com.
About Tanner Health
Tanner Health is a five-hospital non-profit health system providing convenient, personalized health care to communities across west Georgia and east Alabama. Tanner Health physicians and staff provide the latest technology and treatment options to advance the health of our patients. In addition to their regional hospitals and care centres, Tanner operates Tanner Medical Group, one of metro Atlanta’s largest multi-specialty physician groups.
Learn more at Tanner.org.
About Healthliant Ventures
Healthliant Ventures is dedicated to driving innovation, fostering strategic partnerships, and transforming the way healthcare is delivered. Committed to advancing the industry, Healthliant Ventures focuses on developing innovative technologies, fostering strategic partnerships and driving impactful change across the healthcare landscape.
Learn more at Healthliant.com.